BACKGROUND: Immunoglobulin (Ig)G replacement with intravenous or subcutaneous immunoglobulins is a lifelong substitutive therapy in patients with primary antibody deficiencies (PADs). Hemolysis after immunoglobulin therapy was described in patients receiving high immunoglobulin dosages. The issue of hemolysis after immunoglobulin administration at replacement doses has been considered of little clinical significance. STUDY DESIGN AND METHODS: This was a single-center observational study over a 2-year period on immunoglobulin-induced hemolysis in a cohort of 162 patients with PADs treated with immunoglobulin administered at replacement dosages. RESULTS: Six patients had signs and symptoms of immunoglobulin-induced hemolysis. Two additional asymptomatic patients were identified by a short-term study run on 16 randomly selected asymptomatic patients. Alloantibodies eluted from patients' red blood cells (RBCs) had anti-A and Rh specificities (anti-D and anti-C). The immunoglobulins contained alloantibodies with the same specificities of the antibodies eluted from patients' RBCs. CONCLUSION: Hemolysis occurred in patients receiving immunoglobulin at replacement dosages. Polyvalent immunoglobulin preparations contained multiple clinically significant antibodies that could have unexpected hemolytic consequences, as anti-C whose research and titration are not required by the European Pharmacopoeia. The issue of hemolysis in long-term recipients of immunoglobulin treatment administered at replacement dosages should be more widely recognized.

Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment / Quinti, I; Pulvirenti, F; Milito, C; Granata, Guido; Giovannetti, G; La Marra, F; Pesce, ANNA MARIA; Farrugia, A; Coluzzi, S; Girelli, Gabriella. - In: TRANSFUSION. - ISSN 0041-1132. - (2015). [10.1111/trf.12939]

Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment

Quinti, I;Pulvirenti, F;Milito, C;GRANATA, GUIDO;Giovannetti, G;La Marra, F;Coluzzi, S;GIRELLI, Gabriella
2015

Abstract

BACKGROUND: Immunoglobulin (Ig)G replacement with intravenous or subcutaneous immunoglobulins is a lifelong substitutive therapy in patients with primary antibody deficiencies (PADs). Hemolysis after immunoglobulin therapy was described in patients receiving high immunoglobulin dosages. The issue of hemolysis after immunoglobulin administration at replacement doses has been considered of little clinical significance. STUDY DESIGN AND METHODS: This was a single-center observational study over a 2-year period on immunoglobulin-induced hemolysis in a cohort of 162 patients with PADs treated with immunoglobulin administered at replacement dosages. RESULTS: Six patients had signs and symptoms of immunoglobulin-induced hemolysis. Two additional asymptomatic patients were identified by a short-term study run on 16 randomly selected asymptomatic patients. Alloantibodies eluted from patients' red blood cells (RBCs) had anti-A and Rh specificities (anti-D and anti-C). The immunoglobulins contained alloantibodies with the same specificities of the antibodies eluted from patients' RBCs. CONCLUSION: Hemolysis occurred in patients receiving immunoglobulin at replacement dosages. Polyvalent immunoglobulin preparations contained multiple clinically significant antibodies that could have unexpected hemolytic consequences, as anti-C whose research and titration are not required by the European Pharmacopoeia. The issue of hemolysis in long-term recipients of immunoglobulin treatment administered at replacement dosages should be more widely recognized.
2015
.Immunoglobulin therapy;Hemolysis after immunoglobulin;intravenous and subcutaneous immunoglobulin
01 Pubblicazione su rivista::01a Articolo in rivista
Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment / Quinti, I; Pulvirenti, F; Milito, C; Granata, Guido; Giovannetti, G; La Marra, F; Pesce, ANNA MARIA; Farrugia, A; Coluzzi, S; Girelli, Gabriella. - In: TRANSFUSION. - ISSN 0041-1132. - (2015). [10.1111/trf.12939]
File allegati a questo prodotto
File Dimensione Formato  
Quinti_Hemolysis_2015.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 330.56 kB
Formato Adobe PDF
330.56 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/934140
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 20
social impact